Daily Stock Analysis, ARRY, Array Biopharma Inc, priceseries

Array Biopharma Inc. Daily Stock Analysis
Stock Information
Open
0.00
Close
0.00
High
0.00
Low
0.00
Previous Close
0.00
Daily Price Gain
0.00
YTD High
0.00
YTD High Date
Wrong Month 0, 0
YTD Low
0.00
YTD Low Date
Wrong Month 0, 0
YTD Price Change
0.00
YTD Gain
-nan%
52 Week High
0.00
52 Week High Date
Wrong Month 0, 0
52 Week Low
0.00
52 Week Low Date
Wrong Month 0, 0
52 Week Price Change
0.00
52 Week Gain
-nan%
Company Information
Stock Symbol
ARRY
Exchange
NasdaqGM
Company URL
http://www.arraybiopharma.com
Company Phone
3033816600
CEO
Ron Squarer
Headquarters
Colorado
Business Address
3200 WALNUT STREET, BOULDER, CO 80301
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001100412
About

Array BioPharma, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, ONT-380 (ARRY-380), ARRY-797, Ipatasertib, Motolimod, Danoprevir, ARRy-614, GDC-0994, and LOXO-101. Its drugs focuses on the treatment of cancer and inflammatory diseases. The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Description

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, as well as ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer. The company's Phase I drugs include GDC-0994, an ERK inhibitor for cancer; and ARRY-382, a CSF1R inhibitor for cancer, as well as Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.